Insider · CIK 0001177079
Ron Martell
Files at JSPR (Jasper Therapeutics, Inc.). First filing Sep 24, 2025, latest Sep 24, 2025.
Ron Martell files SEC Form 4 as CEO, president and director at JSPR (Jasper Therapeutics, Inc.). Since Sep 24, 2025, Ron Martell has reported 1 open-market buy worth $100k and 0 open-market sells worth $0, the latest filed on Sep 24, 2025.
A track record needs three past buys with six months of prices behind them; Ron Martell has 0, so none is measured yet.
The newest scored trade: bought $100k of JSPR on Sep 22, 2025, filed Sep 24, 2025, scored 78 (notable).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
JSPR: Jasper Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 78Notable | Jasper Therapeutics, Inc. | $100k 41,000 shares | +124% | +9% from low-90% from high |
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 2, 2026 | JSPR Jasper Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +234,000 | $0.00 | $0 | 234,000 | Jan 5, 2026 |
| Sep 22, 2025 | JSPR Jasper Therapeutics, Inc. | POpen-market purchase Voting Common Stock | +41,000 | $2.43 | $100k | 74,118 | Sep 24, 2025 |
| Sep 22, 2025 | JSPR Jasper Therapeutics, Inc. | POpen-market purchase Common Stock Warrant (right to buy)derivative | +41,000 | - | - | 41,000 | Sep 24, 2025 |
| Jun 4, 2025 | JSPR Jasper Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +234,000 | $0.00 | $0 | 234,000 | Jun 6, 2025 |
| Feb 13, 2025 | JSPR Jasper Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +130,000 | $0.00 | $0 | 130,000 | Feb 18, 2025 |
Questions about Ron Martell
Answered from the filings on this page, as of the latest one.
Is Ron Martell buying or selling?
Not in the last 12 months. Ron Martell's latest open-market trade on SEC Form 4 was bought $100k of JSPR on Sep 22, 2025.
How did Ron Martell's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Ron Martell has 0.
Where does Ron Martell file Form 4?
Ron Martell has filed Form 4 at JSPR (Jasper Therapeutics, Inc.) as President, CEO and Director. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.